Arnout Alberts

• Erasmus MC

Background: Our objective was to assess the accuracy of transabdominal ultrasound (TAUS) measured prostate volume in the primary care setting with transrectal ultrasound (TRUS) measured prostate volume by the urologist as the reference test. Furthermore, our objective was to assess whether risk-stratification using TAUS prostate volume by the prim...

Objective To evaluate the feasibility of multivariable risk stratification for early prostate cancer (PCa) detection in a primary healthcare diagnostic facility with regard to its effects on the referral rate and subsequent PCa diagnoses compared to a PSA threshold of 3.0 ng/mL as the current referral indicator. Patients and Methods In 2014, the E...

Background This study aimed to compare the distribution of Prostate Imaging Reporting and Data System (PI-RADS) score and the diagnostic accuracy of magnetic resonance imaging (MRI)–targeted biopsy and systematic biopsy between a Chinese and a Dutch cohort. Materials and methods Our study includes 316 men from Shanghai Changhai Hospital, China, an...

Background: The Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators (ERSPC-RCs) help to avoid unnecessary transrectal ultrasound-guided systematic biopsies (TRUS-Bx). Multivariable risk stratification could also avoid unnecessary biopsies following multiparametric magnetic resonance imaging (mpMRI). Objective: T...

Background In prostate cancer (PCa) screening men and their physicians aim to rule out the presence of potentially life threatening PCa. To date, prostate specific antigen (PSA) testing and systematic prostate biopsy (Bx)—in case of an elevated PSA—are still the main modes of PCa detection. Often uncertainty remains when a PSA-test is <3.0 ng/mL or...

Background According to their guidelines, Dutch general practitioners (GPs) refer men with prostate-specific antigen (PSA) level ≥3.0 ng/mL to the urologist for risk-based patient selection for prostate biopsy using the Rotterdam Prostate Cancer Risk Calculator (RPCRC). Use of the RPCRC in primary care could optimize the diagnostic pathway even fur...

Background: The harm of screening (unnecessary biopsies and overdiagnosis) generally outweighs the benefit of reducing prostate cancer (PCa) mortality in men aged ≥70 yr. Patient selection for biopsy using risk stratification and magnetic resonance imaging (MRI) may improve this benefit-to-harm ratio. Objective: To assess the potential of a risk...

Objective: To investigate biopsy complications and hospital admissions that could be reduced by the use of ERSPC risk calculators (RC). Materials and methods: All biopsies in the Rotterdam section of the ERSPC from 1993 to 2015 were included. Biopsy complications and hospital admission data were prospectively recorded in questionnaires that were...

Objectives: To assess the value of risk-stratification based on magnetic resonance imaging (MRI) and prostate-specific antigen density (PSA-D) in reducing unnecessary biopsies without missing Gleason pattern 4 prostate cancer in men on active surveillance (AS). Patients and methods: In all, 210 men on AS with Gleason score 3 + 3 prostate cancer...

Objective: To study the risk of serial prostate biopsies on complications in men on active surveillance and determine the effect of complications on receiving further biopsies. Materials and methods: In the global Prostate cancer Research International: Active Surveillance (PRIAS) study men are prospectively followed on active surveillance and r...

Background: Multiparametric magnetic resonance imaging (mpMRI) is increasingly used in men with suspicion of prostate cancer (PCa) after negative transrectal ultrasound (TRUS)-guided random biopsy. Risk-based patient selection for mpMRI could help to avoid unnecessary mpMRIs. Objective: To study the rate of potentially avoided mpMRIs after negat...

Men with prostate cancer on active surveillance (AS) are advised to follow strict follow-up schedules and switch to definitive treatment on risk reclassification. However, some men might not adhere to these strict protocols. To determine the number of noncompliers and disease reclassification rates in men not complying with the follow-up protocol o...

The early diagnosis of prostate cancer presents certain dilemmas, and various prostate cancer guidelines have been developed to support clinicians in decision making. However, these guidelines often give contradictory advice and should be appraised critically. We will discuss how the general practitioner (GP) should deal with the frequently used, o...

Prostate-specific antigen-based prostate cancer screening remains a controversial topic. Up to now, there is worldwide consensus on the statement that the harms of population-based screening, mainly as a result of overdiagnosis (the detection of clinically insignificant tumors that would have never caused any symptoms), outweigh the benefits. Howev...

Klinisch significante tumoren met een hooggradige component (Gleason ≥ 7 PCa) zijn goed te visualiseren op MRI. Verdachte laesies (PIRADS ≥ 3) kunnen MRI-gericht worden gebiopteerd. Aangezien tumoren kunnen worden gedetecteerd die met de standaardbiopten worden gemist, zijn MRI-gerichte biopten in het bijzonder zeer interessant bij patiënten met ee...